Two researchers from Johns Hopkins and one researcher from Integrity Pharmaceutical Advisors evaluated the top 1,000 generics in Colorado’s 2019 payer claims. That year, generics cost payers $7.5 million, but if all generic costs were created equal, that figure would have dropped to $873,711, an 88.3 percent decline, they found.
Among the 1,000 generics, 45 of them “had lower-cost therapeutic alternatives of same clinical value,” according to the study, which was published Nov. 2 in JAMA. Of those 45 drugs, the most expensive generics were 15.6 times more costly than their alternatives.
Since patients require a provider’s note to receive a cheaper generic, the study’s authors concluded that insurers and plan sponsors should adjust their formularies to achieve the projected savings, which was about $6.6 million in 2019.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
